03-2914. Manufacturer of Controlled Substances; Notice of Application  

  • Start Preamble

    Pursuant to § 1301.33(a) of title 21 of the Code of Federal Regulations (CFR), this is notice that on July 31, 2002, Cerrilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78664, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

    DrugSchedule
    Cathinone (1235)I
    Methcathinone (1237)I
    N-Ethylamphetamine (1475)I
    N,N-Dimethylamphetamine (1480)I
    Aminorex (1585)I
    4-Methylaminorex (cis isomer) (1590)I
    Gamma hydroxybutyric acid (2010)I
    Methaqualone (2565)I
    Alpha-Ethyltryptamine (7249)I
    Lysergic acid diethylamide (7315)I
    Tetrahydrocannabinols (7370)I
    Mescaline (7381)I
    3,4,5-Trimethoxyamphetamine (7390)I
    4-Bromo-2,5-dimethoxyamphetamine (7391)I
    4-Bromo-2,5-dimethoxyphenethylamine (7392)I
    4-Methyl-2,5-dimethoxyamphetamine (7395)I
    2,5-Dimethoxyamphetamine (7396)I
    2,5-Dimethoxy-4-ethylamphetamine (7399)I
    3,4-Methylenedioxyamphetamine (7400)I
    5-Methoxy-3,4-methylenedioxyamphetamine (7401)I
    N-Hydroxy-3,4-methylenedioxyamphetamine (7402)I
    3,4-Methylenedioxy-N-ethylamphetamine (7404)I
    3,4-Methylenedioxymethamphetamine (7405)I
    4-Methoxyamphetamine (7411)I
    Bufotenine (7433)I
    Diethyltryptamine (7434)I
    Dimethyltryptamine (7435)I
    Psilocybin (7437)I
    Psilocyn (7438)I
    Acetyldihydrocodeine (9051)I
    Benzylmorphine (9052)I
    Codeine-N-oxide (9053)I
    Dihydromorphine (9145)I
    Heroin (9200)I
    Hydromorphinol (9301)I
    Methyldihydromorphine (9304)I
    Morphine-N-oxide (9307)I
    Start Printed Page 6183
    Normorphine (9313)I
    Pholcodine (9314)I
    Acetylmethadol (9601)I
    Allyprodine (9602)I
    Alphacetylmethadol except Levo-Alphacetylmethadol (9603)I
    Alphameprodine (9604)I
    Alphamethadol (9605)I
    Betacetylmethadol (9607)I
    Betameprodine (9608)I
    Betamethadol (9609)I
    Betaprodine (9611)I
    Hydromorphinol (9627)I
    Noracymethadol (9633)I
    Norlevorphanol (9634)I
    Normethadone (9635)I
    Trimeperidine (9646)I
    Phenomorphan (9647)I
    Para-Fluorofentanyl (9812)I
    3-Methylfentanyl (9813)I
    Alpha-methylfentanyl (9814)I
    Acetyl-alpha-methylfentanyl (9815)I
    Beta-hydroxyfentanyl (9830)I
    Beta-hydroxy-3-methylfentanyl (9831)I
    Alpha-Methylthiofentanyl (9832)I
    3-Methylthiofentanyl (9833)I
    Thiofentanyl (9835)I
    Amphetamine (1100)II
    Methamphetamine (1105)II
    Phenmetrazine (1631)II
    Methylphenidate (1724)II
    Amobarbital (2125)II
    Pentabarbital (2270)II
    Secobarbital (2315)II
    Glutethimide (2550)II
    Nabilone (7379)II
    1-Phenylcyclohexylamine (7460)II
    Phencyclidine (7471)II
    1-Piperidinocyclohexanecarbonitrile (8603)II
    Alphaprodine (9010)II
    Cocaine (9041)II
    Codeine (9050)II
    Dihydrocodeine (9120)II
    Oxycodone (9143)II
    Hydromorphone (9150)II
    Diphenoxylate (9170)II
    Benzoylecgonine (9180)II
    Ethylmorphine (9190)II
    Hydrocodone (9193)II
    Levomethorphan (9210)II
    Levorphanol (9220)II
    Isomethadone (9226)II
    Meperidine (9230)II
    Methadone (9250)II
    Methadone-intermediate (9254)II
    Dextropropoxyphene, bulk (non-dosage forms) (9273)II
    Morphine (9300)II
    Thebaine (9333)II
    Levo-alphacetylmethadol (9648)II
    Oxymorphone (9652)II
    Noroxymorphone (9668)II
    Racemethorphan (9732)II
    Alfentanil (9737)II
    Sufentanil (9740)II
    Fentanyl (9801)II

    The firm plans to manufacture small quantities of the listed controlled substances to make deuterated and non-deuterated drug reference standards which will be distributed to analytical and forensic laboratories for drug testing programs.

    Any other such applicant and nay person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration.

    Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than April 7, 2003.

    Start Signature

    Dated: January 27, 2003.

    Laura M. Nagel,

    Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

    End Signature End Preamble

    [FR Doc. 03-2914 Filed 2-5-03; 8:45 am]

    BILLING CODE 4410-09-M

Document Information

Published:
02/06/2003
Department:
Drug Enforcement Administration
Entry Type:
Notice
Document Number:
03-2914
Pages:
6182-6183 (2 pages)
PDF File:
03-2914.pdf